Asian markets are principally rising after AI buying and selling boosted Wall Avenue in a single day

An electronic quotation board displays Nikkei 225 stock prices on the Tokyo Stock Exchange on November 5, 2025 in Tokyo.

Greg Baker | Afp | Getty Images

Asia-Pacific markets opened mostly higher on Tuesday after AI trading lifted major Wall Street indexes overnight.

Nvidia shares rose more than 1% after Reuters said the company plans to begin shipping its H200 chips to China by mid-February. Micron Technology rose about 4%, while Oracle rose more than 3%.

Australia’s S&P/ASX 200 rose 1.1% to close at 8,795.7, marking a fourth straight day of gains.

Japan Nikkei 225 The price ended slightly above the zero line at 50,412.87, extending gains into the third day. The broad-based Topix gained 0.53% to 3,423.25, led by financials and healthcare stocks.

Japan’s Finance Minister Satsuki Katayama reportedly said on Tuesday that the country has a “free hand” in dealing with the recent sharp devaluation of the yen, signaling that currency intervention is not off the table.

The yen weakened sharply on Friday even as the Bank of Japan raised interest rates to a 30-year high, hitting a low of 157.77 against the dollar before rising on Monday and Tuesday. The last trade was at 156.14.

Katayama said the Japanese currency’s fluctuations did not reflect economic fundamentals and called them “speculative.”

South Korea Kospi rose 0.28% to 4,117.32, also snapping a three-day winning streak, but the small-cap Kosdaq slipped 1.03% to 919.56.

Shares of shipbuilding company Hanwha Ocean rose 10% after US President Donald Trump said the company would work with the US Navy to build its new frigates.

Hong Kong Hang Seng Index bucked the trend and fell 0.25%, with materials stocks leading the decline, while the CSI 300 in mainland China rose 0.17%.

Chinese newcomers lit up the Hong Kong market in their debut on Tuesday, with QingSong Health Corporation and Nuobikan Artificial Intelligence Technology rising 134% and 323%, respectively, after their strong, albeit small, initial public offerings.

QingSong Health Corporation’s initial public offering in Hong Kong was met with overwhelming demand: the domestic tranche was subscribed 1,421 times and raised nearly 602 million Hong Kong dollars (about $77 million), according to an exchange filing. The public tranche of Nuobikan in Hong Kong was subscribed 188.74 times and raised HK$303 million.